numares announces FDA 510(k) Submission of AXINON System®, a NMR platform for metabolomics-based, AI-driven Diagnostics
Leading NMR diagnostics company numares AG today announced that the company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AXINON® IVD System, a NMR-platform for AI-driven, metabolomics-based diagnostics. If cleared, AXINON® would become the first NMR-based clinical laboratory system using AI-evaluated metabolic data. Several multi-marker assays for AXINON® will cover numerous unmet medical needs, in order to prevent, diagnose and treat disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005057/en/
numares AXINON® IVD System: The AI-driven AXINON® Software, in combination with advanced NMR technology, refined by numares' proprietary Magnetic Group SignalingTM, allows metabolomics-based precision diagnostics by implementation of various numares' tests, e.g. to identify early kidney rejection in post-transplant surveillance, assess kidney function by improved determination of glomerular filtration rate (GFR) and risk for cardiovascular disease (CVD). (Photo: Business Wire)
The clearance of AXINON® would bring a novel diagnostic approach to clinical laboratories, the combination of several metabolic biomarkers, so-called metabolite constellations, analyzed by advanced nuclear magnetic resonance (NMR) technology and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software.
"This U.S. regulatory filing for its diagnostics platform is an important milestone for numares," said Winton Gibbons, President - US and co-Chief Executive Officer of numares. “After entering into collaborations on joint diagnostics development with analytical instrumentation and solution provider Bruker Corporation in January 2021, and with Mayo Clinic Laboratories in 2019, this FDA submission is the first step in our common endeavor to bring NMR diagnostics into routine clinical use, and make metabolomics-based diagnostics accessible to the patients.”
numares is currently developing multi-marker algorithms for several diagnostic tests on the AXINON® IVD System. These include AXINON® GFRNMR to reliably assess kidney function by improved determination of glomerular filtration rate (GFR). numares expects to submit this test to the FDA also in the first half 2021. The third assay AXINON® renalTX-SCORE® is intended to reliably identify early kidney rejection in post-transplant surveillance, and be submitted to the FDA in 2022. Further multi-marker tests are in development, e.g., for liver disease, cancer detection, and multiple sclerosis.
Dr. Maulik Shah, numares’ Medical Director comments: “AXINON® provides clinical laboratories with a powerful technology that leverages the information-rich metabolome with artificial intelligence to give healthcare professionals new insights into disease diagnosis and management for improved patient outcomes. At the same time, automation capabilities, excellent precision, easy operability will allow easy adaption of the FDA-cleared system by clinical laboratories and will make AXINON® an indispensable routine diagnostic tool in precision medicine.”
“The 510(k) submission of our AXINON® System is an important step and prerequisite to further strengthen commercialization of numares’ products in the United States”, concludes Dr. Volker Pfahlert, co-CEO of numares and chairman of the executive board. “Metabolic disorders are a rapidly increasing problem and major challenge to today’s healthcare systems. Patients will benefit from our approach to consider the patient's metabolome with sophisticated algorithms. Once cleared by the FDA, we believe AXINON® has the potential to meaningfully improve health outcomes and quality of life for millions of patients.”
The AXINON® System consists of AI-based AXINON® Software, ready-to-use AXINON® kits, and an advanced NMR technology, refined by numares’ proprietary Magnetic Group SignalingTM to ensure highly standardized and automated processing of serum or urine samples in high-throughput.
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005057/en/
Contact information
numares
Christiane Proll
Tel.: +49 941 280 949-14
E-Mail:
christiane.proll@numares.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Copeland Advances AI and Digital Strategy with Acquisition of Bueno Analytics21.1.2026 14:00:00 EET | Press release
Copeland, a global provider of compression technologies and controls solutions, announced today that it has entered into an agreement to acquire Bueno Analytics (“Bueno”), an Australia-based company specializing in SaaS solutions that leverage embedded AI and machine learning to deliver building analytics, energy management and operational efficiency across commercial buildings and the cold chain. Bueno’s platform is deployed across several thousand customer sites worldwide, providing broad connectivity, full portfolio visibility and critical operational insights. Buildings account for an estimated 40% of global carbon emissions, with commercial buildings and the cold chain representing a significant share of that impact. The integration of Bueno’s platform with Copeland’s deep domain expertise will deliver a powerful suite of capabilities, including predictive maintenance, energy management, leak detection, workforce efficiency tools and advanced analytics. Together, these technologie
NIRSense, Inc. & Aspen Medical USA (AMUSA): Strengthening Frontline Medicine: U.S.–Developed Tissue Oxygenation Technology Delivered to Ukraine21.1.2026 14:00:00 EET | Press release
Today, NIRSense and Aspen Medical USA (AMUSA) are pleased to announce the donation of 12 portable tissue-ischemia monitoring kits (comprising advanced sensor consoles plus tablets) to the Ministry of Defence of Ukraine (MoD) for deployment in frontline Role-1 and Role-2 casualty care facilities in Ukraine. These investigational prototype systems are provided for use by military medical teams treating extremity-injured personnel (including those who have undergone tourniquet application) to assess and monitor tissue perfusion and oxygenation in real time. Why this matters In the battlefield context, timely recognition of compromised tissue perfusion (particularly in limbs subject to tourniquet use, major soft‐tissue injury or ischemia-reperfusion risk) can make the difference between viable salvage of the limb, avoidance of secondary complications, and optimal patient outcomes. The donated NIRSense kits, which will be administered by the Ukraine MoD under an approved protocol, may provi
Allshares Acquires U.S. Market Leader Stock & Option Solutions, Solidifying Its Position as a Global Leader in Equity Ownership Management21.1.2026 13:00:00 EET | Press release
Allshares, a global provider of equity ownership management software and services, today announced the acquisition of Stock & Option Solutions (“SOS” or the “Company”), a U.S.-based specialist in end-to-end equity compensation and plan administration. Stock & Option Solutions brings a track record of supporting the full life cycle of equity and compensation plan administration. Recognized as one of the Inc. 5000 fastest-growing companies in 2022, the Company has built a strong reputation for supporting organizations across the United States, from early-stage startups to large enterprises. Its platform-agnostic service model enables clients to optimize complex incentive structures across major equity technology systems. This acquisition marks a strategic milestone in Allshares’ expansion, establishing the U.S. as Allshares’ largest and fastest-growing market. By integrating SOS’ deep U.S. expertise, Allshares strengthens its ability to deliver seamless ownership management for clients o
WEF26: ‘Human Capital Is the Key Driver of Economic Competitiveness’21.1.2026 11:33:00 EET | Press release
For economies to remain competitive in the future, they must prioritize investments in human capital, Her Royal Highness Princess Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, told the World Economic Forum (WEF) Annual Meeting 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120585206/en/ Her Royal Highness Princess Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, speaks on human capital and youth empowerment during the opening Saudi House session at the World Economic Forum Annual Meeting 2026 (Photo: AETOSWire) Speaking on a Saudi House panel, HRH commented: “Human capital today is the key driver if you want a competitive modern economy.” She added: “If you empower people and you give them the space to lead, they will take that drive and they will deliver. And when you place the right people in the right place at the r
BPP Signals Next Era of Growth, Unveiling New Global Parent Brand: Lyceum Education Group21.1.2026 11:03:00 EET | Press release
Today marks the launch of Lyceum Education Group, the new parent brand for 11 leading specialist education businesses across the UK, mainland Europe, Canada and Australia. Lyceum Education Group brings together leading specialist education providers, delivering a diverse portfolio of programmes to benefit learners and businesses globally. From its beginnings as BPP almost 50 years ago, to the creation of the Lyceum Education Group brand today, the move reflects the transition to become a leading, global education group, which will be the second largest post-secondary provider in the UK, and the fourth largest in Europe. Since its acquisition by TDR Capital in 2021, the Group has been acquiring new brands which encompass increased specialisms, diversifying its product ranges and entering new global markets. A clear focus for Lyceum Education Group will be emphasising skills development, employability and career progression, delivering impact for learners, businesses and our changing soc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom